Back to Journals » OncoTargets and Therapy » Volume 19
PLK1 Contributes to Autophagy by Regulating MYC Stabilization in Osteosarcoma Cells [Retraction]
This retraction applies to:
published online on 12/09/2019Mo H, He J, Yuan Z, et al. Onco Targets Ther. 2019;12:7527–7536. https://doi.org/10.2147/OTT.S210575
We, the Editors and Publisher of the journal OncoTargets and Therapy, have retracted the published article.
After publication, concerns have been raised by a third party in 2023 about the integrity of the data in Figures 1 and 3 of the article.
Further investigation conducted by the Journal and Publisher confirmed unexpected similarities between the fluorescence microscopy image panels representative of different treatment conditions in Figures 1G and 3D. Upon further review, the Journal and Publisher identified additional integrity concerns present in the Western blot data shown in Figures 2, 3 and 4.
When approached for an explanation, the authors have responded but due to the time that has elapsed since the experiments were conducted, the authors confirmed that the raw data are unavailable. As a result, these concerns cannot be addressed. The authors have agreed to the retraction of this article and apologize for this oversight.
We have been informed in our decision-making by our editorial policies and the COPE guidelines.
The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as ‘Retracted’.
This retraction relates to this paper
© 2026 The Author(s). This work is published and licensed by Dove Medical Press Limited. The
full terms of this license are available at https://www.dovepress.com/terms
and incorporate the Creative Commons Attribution
- Non Commercial (unported, 4.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted
without any further permission from Dove Medical Press Limited, provided the work is properly
attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.
